This is Thomas Sullivan's Typepad Profile.
Join Typepad and start following Thomas Sullivan's activity
Join Now!
Already a member? Sign In
Thomas Sullivan
Columbia, Maryland
Former political consultant who founded Rockpointe, Inc. a bio-medical education company in 1995.
Interests: marketing, politics, baseball, cycling, medicine, university of florida sports, medical education, track and cross country, driving kids to various practices
Recent Activity
Image
On March 24th, West Virginia’s Governor, Earl Ray Tomblin, approved SB 267, which repeals the state’s Prescription Drug Advertising Expense Reporting requirement. West Virginia law required pharmaceutical manufacturers doing business in the state to disclose all expenditures for advertising and... Continue reading
Posted 18 hours ago at Policy and Medicine
Image
This time last year, we analyzed 2014’s sustainable growth rate (SGR) fix. Although a bipartisan group of lawmakers announced they had reached a deal on legislation to repeal the SGR, it ultimately gave way to a temporary solution. One year... Continue reading
Posted yesterday at Policy and Medicine
Image
The first U.S. biosimilar is one step closer to entering the marketplace. Last week, U.S. District Judge Richard Seeborg of the Northern District of California denied Amgen's request for a preliminary injunction to block Sandoz from selling its version of... Continue reading
Posted 2 days ago at Policy and Medicine
Image
Tomorrow, March 24, Arnold and Porter will be hosting a webcast entitled "Beyond Product Launch: Navigating FDA Post-Market Requirements for mHealth and Health IT." Click here to RSVP to this event. This is the first presentation in Arnold and Porter's... Continue reading
Posted 3 days ago at Policy and Medicine
Image
Life sciences companies are an “increasingly popular target of securities fraud class action lawsuits,” a recent survey by Dechert LLP has found. Securities class actions against pharmaceutical, biotechnology, and medical companies more than doubled last year, to 39 cases compared... Continue reading
Posted 3 days ago at Policy and Medicine
Image
Last week, Newsweek published an article entitled “The Ugly Civil War in American Medicine,” in which the author derided the American Board of Internal Medicine’s (ABIM) certification process for doctors. The author accused the ABIM of requiring unnecessary testing requirements... Continue reading
Posted 6 days ago at Policy and Medicine
Image
On March 11, the Oregon House of Representatives introduced House Bill 3486, which would require pharmaceutical manufacturers to file an annual report with the Oregon Health Authority on costs in the previous year associated with prescription drugs that cost $10,000... Continue reading
Posted 7 days ago at Policy and Medicine
Image
In August of 2012, Johnson & Johnson paid a $181 million multi-state consumer protection settlement to resolve charges that the company marketed its antipsychotic drug Risperdal for off-label uses. In November of 2013, J&J paid $2.2 billion to resolve False... Continue reading
Posted Mar 18, 2015 at Policy and Medicine
Image
The HHS Office of Inspector General (OIG) yesterday announced that Sandoz Inc. will pay $12.64 million to settle allegations it misrepresented drug pricing data to the Medicare program. According to the OIG press release, the Sandoz settlement is the largest... Continue reading
Posted Mar 17, 2015 at Policy and Medicine
Image
Last year saw the release of two large physician databases—Open Payments and the “Medicare Provider Utilization and Payment Data” files, which contain Medicare Part B fee-for-service payments, listed by physician. While the Sunshine Act was many years coming, the Medicare... Continue reading
Posted Mar 16, 2015 at Policy and Medicine
Image
The ninth International Pharmaceutical Compliance Congress and Best Practices Forum is returning to Brussels, where the first was held back in June 2007. The Congress started to bring together company compliance professionals, regulators, lawyers, and consultants from around the world... Continue reading
Posted Mar 13, 2015 at Policy and Medicine
Image
HHS-OIG recently released their 2015 Health Reform Oversight Plan. The agency plans to hone in on the Affordable Care Act during 2015, with “primary focus” on the health insurance marketplaces. Health Insurance Marketplaces OIG’s Oversight Plan states that their marketplace... Continue reading
Posted Mar 13, 2015 at Policy and Medicine
Image
CareFusion Corp. last year paid $40.1 million to settle allegations that it offered kickbacks to doctors in violation of the False Claims Act. Last week, the Department of Justice announced a settlement with one of the doctors implicated in that... Continue reading
Posted Mar 12, 2015 at Policy and Medicine
Image
Today we posted an article on Europe's medtech association's recommendation that companies phase out direct sponsorship of conference attendees. The European pharmaceutical association EFPIA has not instituted such a ban, opting instead for a Disclosure Code that parallels many attributes... Continue reading
Posted Mar 11, 2015 at Policy and Medicine
Image
On October 15, 2014, MedTech Europe, an alliance between the European Diagnostics Manufacturers Association (EDMA) and the Board of the European Medical Technology Industry Association (Eucomed), recommended that their member companies phase out “direct sponsorship” of healthcare professionals to third... Continue reading
Posted Mar 11, 2015 at Policy and Medicine
Image
The Centers for Medicare and Medicaid Services (CMS) hosted a call today to assist stakeholders with the data submission process for Open Payments. During the call, Doug Brown covered a number of issues that applicable manufacturers and GPOs have been... Continue reading
Posted Mar 10, 2015 at Policy and Medicine
Image
The Board of Directors of the National Legislative Association on Prescription Drug Prices (NLARx) has voted to dissolve. The NLARx was formed in 2000 as a coalition of state legislators that set their sights on the pharmaceutical industry’s pricing of... Continue reading
Posted Mar 10, 2015 at Policy and Medicine
Image
Today, the Centers for Medicare and Medicaid Services (CMS) released five new operational FAQs that can help stakeholders working towards their data submission. As a reminder, CMS will be hosting a call tomorrow for Q&As related to registration, data submission,... Continue reading
Posted Mar 9, 2015 at Policy and Medicine
Image
On Tuesday, March 10, 2015 1:30 p.m. – 2:30 p.m. (EST), the Centers for Medicare and Medicaid Services is hosting a live Question & Answer Session. The session will cover questions related to registration, data submission, and attestation. It should... Continue reading
Posted Mar 9, 2015 at Policy and Medicine
Image
Today, the Food and Drug Administration approved Zarxio (filgrastim-sndz), the first biosimilar product approved in the U.S. Sandoz, Inc.’s Zarxio is biosimilar to Amgen Inc.’s Neupogen (filgrastim), which was originally licensed in 1991. The approval comes two months after an... Continue reading
Posted Mar 6, 2015 at Policy and Medicine
Image
Are the patient outcomes of newly trained surgeons comparable to the outcomes of experienced surgeons performing the same types of surgery at the same hospitals? A new study examined this question and came to a surprising conclusion: there were "no... Continue reading
Posted Mar 6, 2015 at Policy and Medicine
Image
CBI’s Pharmaceutical Compliance Congress had an impressive array of presenters this year. The government speakers were all instructive and enlightening, especially the SEC address, which we highlighted yesterday. The Department of Justice panel also provided a helpful look into their... Continue reading
Posted Mar 5, 2015 at Policy and Medicine
Image
At yesterday's session of CBI's Pharmaceutical Compliance Conference in Washington, DC, Andrew Ceresney, Director of Enforcement at the Securities and Exchange Commission, provided compliance officers with an eye-opening look at the many ways SEC seeks out violations of the Foreign... Continue reading
Posted Mar 4, 2015 at Policy and Medicine
Image
Pharmaceutical and device manufacturers operating in France must brace for more extensive reporting requirements under the French Sunshine Act, or “Loi Bertrand.” Last week, the Conseil d’Etat, the French Government’s “advisor in matters concerning the preparation of draft legislation, ordinances... Continue reading
Posted Mar 3, 2015 at Policy and Medicine
Image
Last week, in our Vermont transparency update, we wrote that Vermont’s Attorney General enforced the state’s Prescribed Product Gift Ban and Disclosure Law for the first time in nearly a year. Now, the AG's office just posted another enforcement document... Continue reading
Posted Mar 3, 2015 at Policy and Medicine